GlassScriptPhysician profile
Lata Aluri
NPI 1467581736
$8,103.92
in general payments reported to CMS, 2019-2025
65 companies · $1,074 in 2025
The $1,074 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32.19 · 2020: $183 · 2021: $420 · 2022: $897 · 2023: $2,947 · 2024: $2,551 · 2025: $1,074.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,488 · Education: $82.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,488.35 |
| Education | $82.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $659.65 | 2020-2025 | Tecvayli, Imbruvica, Talvey |
| Novartis Pharmaceuticals Corporation | $566.35 | 2022-2024 | Kisqali |
| Astrazeneca Pharmaceuticals LP | $541.28 | 2020-2025 | Lynparza, Imfinzi, Enhertu |
| Merck Sharp & Dohme LLC | $527.44 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Abbvie INC. | $463.55 | 2022-2025 | Venclexta |
| Celgene Corporation | $437.30 | 2022-2025 | Reblozyl, Pomalyst, Pomalyst |
| Incyte Corporation | $325.05 | 2021-2025 | Monjuvi, Jakafi, Zynyz |
| Pfizer INC. | $318.78 | 2020-2025 | |
| Amgen INC. | $268.01 | 2020-2023 | Kyprolis, Blincyto, Lumakras |
| Daiichi Sankyo INC. | $256.29 | 2021-2025 | Enhertu, Vanflyta, Injectafer |
| Mirati Therapeutics, INC. | $238.12 | 2023 | Krazati |
| Glaxosmithkline, LLC. | $219.26 | 2023-2025 | Ojjaara, Jemperli, Zejula |
| Genzyme Corporation | $209.89 | 2021-2024 | |
| Seagen INC. | $199.70 | 2021-2023 | Adcetris, Tukysa |
| Bayer Healthcare Pharmaceuticals INC. | $186.52 | 2022-2025 |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lata Aluri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.